【摘要】 目的:观察吉西他滨联合顺铂(GP)一线治疗triple-negative(ER、PR、HER-2均阴性)晚期转移性乳腺癌的疾病进展时间、疗效和安全性。方法:2008年1月-2010年4月共41例经免疫组化检查证实为tri-ple-negative的晚期乳腺癌初治患者参与研究。患者接受吉西他滨联合顺铂方案治疗:吉西他滨1000mg/m2,静脉滴注30min,d1、d8;顺铂25mg/m2静脉滴注d1-3天,21天重复。结果:全组41例共完成160个周期的治疗,中位数4个周期,范围2-6个周期,均可评价疗效。完全缓解(CR)2例(4.88%),部分缓解(PR)21例(51.22%),病情稳定(SD)7例(17.07%),病情进展(PD)11例(26.83%)。临床总缓解率(CR+PR)56.10%;疾病控制率(CR+PR+SD)73.17%;中位疾病进展时间(mTTP)8.4个月,1年生存率65.85%。不良反应主要为Ⅰ-Ⅱ度骨髓抑制、末梢神经毒性、胃肠道反应、轻度肝功能损伤等。结论:吉西他滨联合顺铂一线治疗triple-negative晚期转移性乳腺癌患者,初步观察疗效较好,不良反应可耐受,值得进一步研究。更多还原

【Abstract】 Objective:To observe the therapeutic effect and drug tolerance of gemcitable combined with cisplatin in the first line treatment of triple-negative metastatic breast cancer.Methods: Forty-one patints with immunohistochemical proved tiple-negative metastatic breast cancer were enrolled.The patients received gemcitable 1000mg/m2(on day 1 and day 8)and cisplatin 25mg/m2(from day 1 to 3).Results:A total of 160 cycles were given to 41 patients(median 4;range 2-6 cycles).The treatment response was evaluable in all patients of 41 patients.2 received complete remission(CR),21 partial remission(CR),7 stable diease(SD),11 progressive diease(PD).Response rate(CR+PR) was 56.10%.Ⅰ-Ⅱness control rate(CR+PR+SD) was 73.17%;The median time to progress(mTTP) was 8.4 months.The median 1-year survival rate was 65.85%.The major adverse events were grade Ⅰ-Ⅱ myelosuppression,peripheral neurologic,nausea and vomiting,some patients had and hepatic dysfunction.Conclusion:The combination of gemcitable and cisplatin is an effective and well tolerated regimen for the patients with triple-negative metastatic breast cancer.更多还原